Ciardullo S, et al. - This cross-sectional analysis was conducted to determine the impact of statin use on non-alcoholic fatty liver disease (NAFLD) severity in patients suffering from type 2 diabetes (T2D). For this purpose, data from the 2017–2018 cycle of the National Health and Nutrition Examination Survey were utilized. The study sample included 744 patients (age: 61 ± 1 years, BMI: 33.3 ± 0.5 Kg/m ² ). Presence of NAFLD (controlled attenuation parameter ≥ 274 dB/m) was evident in 74.9% of patients and advanced fibrosis was present in 14.5%. Lower odds of advanced fibrosis were reported in relation to statin use, following adjustment for age, gender, race-ethnicity, BMI, albumin, total cholesterol, HbA1c, triglycerides and liver enzymes. Since there are no approved therapies for NAFLD-fibrosis, therefore, initiating specific randomized controlled trials with statins would be reasonable.